knowledge -WSS

knowledge

author：knowledge 2025-09-06 03:28:03 - browse：1

Two people in protective equipment work in a lab. — JUAN MABROMATA/AFP via Getty Images

Biosimilars are no longer a new and untested class of medicines. Today, they provide critical treatment options across multiple therapeutic areas. Since the Biologics Price Competition and Innovation Act of 2009 created a regulatory pathway for biosimilar medicine review in the U.S., 37 biosimilars have come to market offering the potential to increase patient choice and cost savings. And according to the 2023 analysis from IQVIA, biosimilars are expected to generate $181 billion in savings for the U.S. health care system over the next five years.

This progress is due, in part, to thoughtfully considered, scientifically robust regulatory standards, which have instilled confidence among health care providers and patients while protecting safety. As a former associate director of therapeutic biologics at the Food and Drug Administration, I had the privilege of helping create and lead implementation of the regulatory framework for biosimilars. The FDA took great care to apply appropriate scientific rigor to the development and approval standards. While I have since moved to Amgen, my goals have remained focused on biosimilar product quality and efficacy, patient safety, and prescriber confidence.

More than a decade later, collective efforts by biosimilar manufacturers and the FDA are paying off.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： The SUPPORT Act is critical to fighting the opioid crisis

focus

WSS

DeSantis can now import cheaper drugs. But will Biden get credit?

Heart disease in astronauts blamed on cosmic radiation

Idaho abortion case may prompt more restrictions in other states

How I ended up pumping milk in a bathroom stall at JPM 2024

Risky weight loss products often used by teens globally, per study

Generative AI mines health records to identify patients’ social needs

entertainment

knowledge

hotspot

As demand for Covid shots wanes, Moderna seeks its next success

JPM 2024: Nvidia claims we're in biological revolution. Are we?

Dobbs anniversary: the lost opportunity of abortion as health care

Risky weight loss products often used by teens globally, per study

Dobbs anniversary: the lost opportunity of abortion as health care

Doulas covered by Medicaid under New York's new plan

Affirmative action in medical school literally saved lives

Listen: Biotech layoffs, eye drug drama, & gene therapy milestones

Psychedelics group wrestles with new pharma identity

DeSantis can now import cheaper drugs. But will Biden get credit?

entertainment

As JPM 2024 winds down, some health tech firms project optimism

Who is Jack Smith, the special counsel overseeing the DOJ's Trump probes?

JPM 2024: FogPharma’s CEO unveils ‘contrarian’ plan in oncology

DeSantis can now import cheaper drugs. But will Biden get credit?

Heart disease and mental health: A look at cardiac psychology

HHS names first

explore

hotspot

focus

focus